BNET Industries

Celgene Corp.

(CELG) is in the Pharma Industry

Market Cap:$22.0B
Last Fiscal Year Sales:$1.4B
  • Public
  • US
Dow Jones Description

Celgene keeps leprosy treatment options intact. Founded in 1980 and headquartered in Summit, NJ, Celgene Corporation (NASDAQ-GS: CELG) discovers, develops, and commercializes therapeutic products for immune-inflammatory diseases and cancer. The company offer Thalomid for erythema nodosum leprosum, Revlimid for transfusion-dependent anemia, and Focalin for ADHD, and has several drugs in development. Products in its pipeline will treat psoriasis, inflammatory diseases, and a wide range of cancers. It has collaborative and strategic agreements with Novartis and Pharmion. The company had 2005 revenue of about $536.9 million and has about 945 full-time employees. In June 2006, the company's REVLIMID, in combination with Dexamethasone's supplemental new drug application (sNDA) was granted approval by the FDA for treatment of Multiple Myeloma. This was the third FDA approval for the company in six months.

PresidentRobert J. Hugin
Number of Employees 2,441
Contact Information

86 Morris Ave

Summit, New Jersey 07901

www.celgene.com

1 908 673 9000

NAICS Code Pharmaceutical and Medicine Manufacturing: 32541

Recent Events

  • Boulder-area CEOs' compensation in-depth

    6/22/09 - Joint Venture / Alliance - View Story

  • Celgene initiated with "buy"

    6/16/09 - Bond / Stock Rating - View Story

  • Analysts: Celgene arthritis drug could sell well

    6/16/09 - Bond / Stock Rating - View Story

  • GlobeImmune and Celgene announce $500 million oncology deal

    6/10/09 - Joint Venture / Alliance - View Story

  • GlobeImmune, Celgene Reveal Strategic Global Oncology Alliance - Update

    5/15/09 - Joint Venture / Alliance - View Story

  • BRIEF-Goldman downgrades U.S. large cap biotech sector to neutral

    5/08/09 - Bond / Stock Rating - View Story

  • Celgene downgraded to "neutral"

    5/01/09 - Bond / Stock Rating - View Story

  • Market Maker Surveillance Report. Top 6 Losing Stocks With Lowest Price Friction For May 1,...

    5/04/09 - Joint Venture / Alliance - View Story

  • Fresh signs of recovery bolster Wall Street

    5/02/09 - Financial Announcement - View Story

  • Pharmaceuticals lose ground as biotechs gain

    4/22/09 - Bond / Stock Rating - View Story

  • Top five executives' stock worth more than $57 million

    4/21/09 - Merger / Acquisition - View Story

  • Analyst Picks and Pans: APOL, CELG, ONNN, ZZZ

    4/01/09 - Bond / Stock Rating - View Story

  • Celgene "overweight," target price reduced

    4/01/09 - Bond / Stock Rating - View Story

  • Celgene "buy," target price reduced

    4/01/09 - Bond / Stock Rating - View Story

  • Celgene sees Q1 earnings below Street view; stock plunges in after-hours - Update

    4/01/09 - Product Announcement - View Story

  • EARNINGS PREVIEW: Biotechs Hit By Credit Woes; Deals Seen

    4/13/09 - Financial Announcement - View Story

  • Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits

    1/29/09 - Financial Announcement - View Story

News & Analysis

celgene corp. - All News and Analysis

Those who viewed this also viewed...

Decision Makers

Name (plus bio) Position
Robert J. Hugin President
David W. Gryska Chief Financial Officer
James R. Swenson Chief Accounting Officer & Controller
Jerome Zeldis Chief Medical Officer
Srinivas Akkaraju Chief Financial Officer
David Stirling Executive Vice President, Pharmaceutical Res & Development
Francis Brown Senior Vice President, Sales, Marketing
Joseph J. Day Senior Vice President, Business Development & Technology Operations
Mark Alles Vice President, Marketing
Michael Vander Zwan Vice President, Quality Assurance & Compliance
Steven D. Thomas Vice President, Regulatory Affairs & Project Management
Brian Gill Director, Public Relations & Investor Relations
Catherine Elflein Director of Treasury and Risk Management
Dale M Lombardi Director of Licensing and Business Development
Jesus Ma Rodriguez Sanchez Marketing and Sales Director
Jose Baquero Calabuig Medical Affairs Head
Jose Miguel Fernandez Ramil Regulatory Affairs and Institutionals Relations Di
Michael E Williams Consultant
Jack L. Bowman Director

Board of Directors

Name (plus bio) Position
Sol J. Barer PhD Chairman of the Board
Arthur H. Hayes Jr. Board of Directors
Ernest Mario PhD Board of Directors
Frank T. Cary Board of Directors
Gilla Kaplan PhD Board of Directors
Inder Verma Board of Directors
James Loughlin Board of Directors
Michael D. Casey Board of Directors
Richard Morgan Board of Directors
Rodman L. Drake Board of Directors
Walter L. Robb PhD Board of Directors
Organization Position Status
Rare Diseases Clinical Research Network President and Chief Operating Officer Current
Pharmion Corporation President and Chief Operating Officer Current
Lead Discovery President and Chief Operating Officer Current
Celgene Corporation President Current
Celgene Corporation Chief Operating Officer Current
Angiox Independent Director, Chair of Audit Committee Current
Cancer Immunity Board of Directors Current
Family Promise Board of Directors Current
Celgene Corporation Board of Directors Current
Coley Pharmaceutical Group Inc. Director Current
Atlantic Health System Inc. Director Current
Rare Diseases Clinical Research Network Senior Vice President and Chief Financial Officer Former
Multiple Myeloma Senior Vice President and Chief Financial Officer Former
Celgene Corporation Senior Vice President Former
The Medicines Company Independent Director, Chair of Audit Committee Former
United States, Inc. Marine Corps Infantry Officer Former
University of Virginia M.B.A. Former
Princeton University A.B. Former
Organization Position Status
Multiple Myeloma Senior Vice President & Chief Financial Officer Current
Pharmion Corporation Senior Vice President & Chief Financial Officer Current
Celgene Corporation Chief Financial Officer Current
Rare Diseases Clinical Research Network Senior Vice President & Chief Financial Officer Current
Seattle Genetics, Inc. Board of Directors Current
CoTherix, Inc. Board of Directors Current
Seattle Genetics, Inc. CEO, Biotechnology Former
Scios, Inc. Chief Financial Officer Former
Scios, Inc. Senior Vice President Former
Young Corporation Partner Former
Ernst & Young partner Former
Strategic Consulting Group Principal Former
Golden Gate University M.B.A. Former
Golden Gate University B.A. In Accounting Former
Loyola University B.A. In Accounting Former
Seattle Genetics, Inc. member Former
CoTherix, Inc. member Former
Organization Position Status
Celgene Corporation Chief Accounting Officer & Controller Current
Celgene Corporation Controller & Chief Accounting Officer Current

Dr. Zeldis is Chief Medical Officer of Celgene Corporation, Warren, NJ. He is currently Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has been a board member of a few start-up biotechnology companies and is currently on the board of the Semorex Corporation, ImmuneRegen, the NJ Chapter of the Arthritis Foundation and the Castleman's Disease Organization. He currently has published 95 peer reviewed articles and 24 reviews, book chapters, and editorials.

Organization Position Status
Celgene Corporation Chief Medical Officer Current
Celgene Corporation Vice President, Medical Affairs Current
Robert Wood Johnson Medical School - University of Medicine & Dentistry of New Jersey Associate Professor of Clinical Medicine Current
Havens, Inc. Current
Immuneregen Biosciences Board of Directors Current
Semorex Inc. Board of Directors Current
Massachusetts General Hospital Former
Yale University M.S. Former
Organization Position Status
Celgene Corporation Chief Financial Officer Current
The Panorama Capital, LLC Managing Director Former
Pharmos Corporation Co-Founder and Managing Director, Panorama Capital Current
Panorama, Inc. Co-Founder Current
Vela Pharmaceuticals, Inc. Current
New Leaf Current
Barrier Therapeutics, Inc. Director Current
Amarin Corporation Plc Board of Directors Current
Itero Biopharmaceuticals, Inc. Board of Directors Current
Pharmos Corporation Board of Directors Current
Seattle Genetics, Inc. Director Current
The Panorama Capital, LLC Co-Founder Former
Genentech, Inc. Senior Manager Former
Strategic Consulting Group Principal Former
Stanford University School of Medicine M.D. Former
Rice University Ph.D. in Immunology Former
Stanford University M.D. Former
Rice University B.A. Degrees Former
Rice University Degrees In Biochemistry and Computer Science Former
Organization Position Status
Celgene Corporation Executive Vice President, Pharmaceutical Res & Development Current
Organization Position Status
Celgene Corporation Senior Vice President, Sales, Marketing Current
Organization Position Status
Celgene Corporation Senior Vice President, Business Development & Technology Operations Current
Organization Position Status
Celgene Corporation Vice President, Marketing Current
Organization Position Status
Celgene Corporation Vice President, Quality Assurance & Compliance Current
Organization Position Status
Celgene Corporation Vice President, Regulatory Affairs & Project Management Current
Organization Position Status
Celgene Corporation Director, Public Relations & Investor Relations Current
Celgene Corporation Director, Public Relations & Investor Relations Former
Organization Position Status
Celgene Corporation Director of Treasury and Risk Management Current
Monmouth Real Estate Investment Corporation Board of Directors Current
Casa of NJ Board of Directors Current
Seton Hall University Masters of Business Administration Former
Seton Hall University Bachelor of Science Former

Dale M. Lombardi leads the Company as Chief Executive Officer. Mr. Lombardi has been involved in biomedical research and development in the pharmaceutical industry since 1978 as a physiologist, pharmacologist, drug development project manager, clinical project leader, and licensing and business development executive. As clinical project leader, Mr. Lombardi was responsible for the submission of two new drug applications to the FDA that were approved for marketing (MiniPress XL and ProCardia GITS). He was also responsible for a number of important business advances and licenses during his tenure as Associate Director, Licensing and Business Development at Pfizer, Inc., Director of Licensing and Business Development for Celgene Corporation, Director of the Center for Technology Transfer at the University of Pennsylvania and Vice President, Global Corporate Licensing at British Technology Group. Mr. Lombardi was also responsible for venture capital financing for pharmaceuticals and start-up companies during his tenure as Senior Vice President for Technology Management & Funding, LP.

Organization Position Status
Secant Pharma, LLC Chief Executive Officer Current
Celgene Corporation Director of Licensing and Business Development Current
Celgene Corporation Board of Directors Current
Pfizer Inc. Board of Directors Former
Organization Position Status
Celgene Corporation Marketing and Sales Director Current
Organization Position Status
Celgene Corporation Medical Affairs Head Current
Organization Position Status
Celgene Corporation Regulatory Affairs and Institutionals Relations Di Current
Organization Position Status
Quest Meded Consultant for Celgene and Amgen Current
Celgene Corporation Consultant Current
Organization Position Status
Rare Diseases Clinical Research Network Chairman and Chief Executive Officer Current
Pharmion Corporation Chairman and Chief Executive Officer Current
Lead Discovery Chairman and Chief Executive Officer Current
Celgene Corporation Chairman of the Board Current
Semorex Inc. Director Current
Biotechnology Council of New Jersey, Inc Board of Directors Current
Global Capital Associates Board of Directors Current
Multiple Myeloma Chairman and Chief Executive Officer Former
Celgene Corporation Chief Executive Officer Former
Rare Diseases Clinical Research Network President Former
Celgene Corporation COO Former
Rutgers University Ph.D. In Organic and Former
Organization Position Status
Quantrx Biomedical Corporation Director of Quantrx Current
Quantrx Biomedical Corporation Board of Directors Current
Celgene Corporation Board of Directors Current
Myriad Genetics, Inc. Board of Directors Current
Tapestry Pharmaceuticals Inc. Board of Directors Current
New York Medical College Chief Executive Officer Former
Penn State College of Medicine President Former
New York Medical College President Former
Penn State College of Medicine Professor of Medicine Former
New York Medical College Dean Former
Weill Medical College of Cornell University M.D. Former
University of Oxford M.S. Former
Santa Clara University B.A. Former
Organization Position Status
Prestwick Pharmaceuticals, Inc Chairman, Pharmaceutical Product Development, Chairman and CEO, Capnia Current
CAPNIA, Inc. Chairman & CEO Current
Park Avenue Equity Partners Partner Current
ICOS Corporation Lead Director Current
University of Rhode Island Adjunct Professor Current
Duke University Trustee Current
University of Maryland Advisor Current
Galileo Pharmaceuticals, Inc. Chairman of the Board of Directors Current
Duke University Health System Board of Directors Current
Multiple Myeloma Board of Directors Current
Pathway Diagnostics Corporation Board of Directors Current
Rare Diseases Clinical Research Network Board of Directors Current
Pharmaceutical Product Development, Inc. Director Current
Maxygen, Inc. Board of Directors Current
Celgene Corporation Board of Directors Current
Boston Scientific Corporation Board of Directors Current
Guidant Board of Directors Current
Pharmion Corporation Board of Directors Current
Lead Discovery Board of Directors Current
Caliper Life Sciences, Inc. Vice-Chairman Current
The Reader's Digest Association, Inc. Director Current
Ardea Biosciences, Inc.De Chief Executive Officer Former
Alza Technologies Corp CEO Former
Reliant Pharmaceuticals, Inc. Chief Executive Officer Former
Reliant Pharmaceuticals, Inc. Chief Executive Former
Bay City Capital LLC Vice President Former
Lee Enterprises, Inc. Publisher Former
ALZA Corporation Executive Officer Former
Squibb Corporation Former
ALZA Corporation Chairman Former
Alza Technologies Corp Chairman Former
The American Foundation Chairman Former
Reliant Pharmaceuticals, Inc. Chairman of the Board Former
Ardea Biosciences, Inc.De Chairman Former
Duke University Health System Chairman of The Board Former
Alexza Pharmaceuticals, Inc. Board of Directors Former
University of Rhode Island Master's and Doctoral Degrees In Physical Sciences Former
Rutgers University B.S. In Pharmacy Former
Princeton University Ab Degree Former
Organization Position Status
Celgene Corporation Board of Directors Current
International Business Machines Corporation Chief Executive Officer Former
International Business Machines Corporation Chairman of the Board Former

Gilla Kaplan Ph.D. has been one of our Directors since April 1998 and is a member of the Audit Committee of our Board of Directors. She is head of the Laboratory of Mycobacterial Immunity and Pathogenesis at The Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark, New Jersey, where she was appointed full member in 2002. Dr. Kaplan is also Professor of Medicine at UMDNJ. Previously, Dr. Kaplan was an Immunologist in the Laboratory of Cellular Physiology and Immunology at The Rockefeller University in New York where she was an Associate Professor.

Organization Position Status
Celgene Corporation Board of Directors Current
The Rockefeller University Immunologist In the Laboratory of Cellular Physiology and Immunology Former
Organization Position Status
Greenwich Biotech Partners Board of Directors Current
Celgene Corporation Board of Directors Current
Organization Position Status
AVI BioPharma, Inc. Chairman Current
AVI BioPharma, Inc. Director Current
Celgene Corporation Director Current
American Cyanamid Company Executive Vice President Former
The Johns Hopkins University member Former
NeoRx Corporation chairman Former
Johnson & Johnson Group Chairman Former
Targeted Genetics Corporation Board of Directors Former
Western Washington University B.Ed. Former

Jim Loughlin was named to the Celgene Board of Directors in January 2007, and serves as a member of the Audit Committee. Mr. Loughlin, an experienced corporate director served as the National Director of the Pharmaceuticals Practice at KPMG, including a five-year term as member of the Board of Directors of KPMG LLP. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees.

Organization Position Status
Celgene Corporation Board of Directors Current
Multiple Myeloma Board of Directors Current
Pharmion Corporation Board of Directors Current
Lead Discovery Board of Directors Current
Rare Diseases Clinical Research Network Board of Directors Current
Celgene Corporation Member of the Audit Committee Current
Organization Position Status
DURECT Corporation Director, Chairman of the Nominating and Governance Committee Current
Allos Therapeutics, Inc. Pharmaceutical Industry Consultant Current
DURECT Corporation Director Current
Cholestech Corporation Director Current
Lead Discovery Board of Directors Current
AVI BioPharma, Inc. Director Current
Bone Care International, Inc. Director Current
Celgene Corporation Board of Directors Current
Inex Pharmaceuticals Corporation Director Current
Orthologic Corporation Director Current
Allos Therapeutics, Inc. Director Current
Multiple Myeloma Committee Member Current
Pharmion Corporation Committee Member Current
Rare Diseases Clinical Research Network Committee Member Current
Genetic Therapy, Inc. President Former
Genetic Therapy, Inc. Chief Operating Officer Former
Ortho Pharmaceutical Corporation Vice President, Sales and Marketing Former
Johnson & Johnson Vice President of Sales and Marketing Former
Organization Position Status
Motif Biosciences, Inc CEO Current
Amphion Innovations, Plc Chief Executive Officer Current
Firestar Software, Inc. Executive Director Current
Amphion Founder Current
Axcess, Inc. Chairman of The Board Current
Axcess International, Inc. Chairman Current
Motif Biosciences, Inc Chairman Current
Myconostica Ltd Board of Directors Current
Celgene Corporation Board of Directors Current
Firestar Software, Inc. Board of Directors Current
Amphion Innovations, Plc Board of Directors Current
Orbis International Board Member Current
Quidel Corporation Director Current
Durham Scientific Crystals Director Current
Wellgen, Inc. Director Current
Celgene Corporation Member Current
Wellgen, Inc. Chairman and CEO, Amphion Innovations Plc Former
Schroders plc Former
SEQUUS Pharmaceuticals Former
Axcess, Inc. Director Former
University of Auckland Bachelors Degree Former
University Corp. Former
Wellgen, Inc. Member Former
Organization Position Status
The Student Loan Corporation Managing Partner Current
The Student Loan Corporation Chair, Audit Committee Current
Celgene Corporation Board of Directors Current
Crystal River Capital, Inc. Director Current
The Student Loan Corporation Board of Directors Current
Excelsior Funds, Inc Director Current
Jackson Hewitt Tax Service Inc. Board of Directors Current
Pharmion Corporation Board of Directors Current
Parsons Brinckerhoff Inc. Board of Directors Current
Lead Discovery Board of Directors Current
Pharmion Corporation Committee Member Current
Celgene Corporation Member of the Audit Committee Current
Multiple Myeloma Committee Member Current
Rare Diseases Clinical Research Network Committee Member Current
Cresap Incorporated Former
Organization Position Status
The Fox Group Inc. Managing Partner of Counter Point Ventures Current
FA Technology Ventures advisor Current
First Albany Companies Inc. Current
Evident Technologies, Inc. Current
Admetech Foundation and Partners Chairman Current
Glenmont Partners, LLC Board of Directors Current
Intelligent First Aid, Inc. Board of Directors Current
Celgene Corporation Board of Directors Current
The Fox Group Inc. Board of Directors Current
Inverters Unlimited, Inc Board of Directors Current
MTI Instruments Inc. Board of Directors Current
Plug Power Inc. member Current
Mechanical Technology Inc. member Current
Celgene Corporation member Current
General Electric Company Senior Vice President Former
Vantage Management Co., Inc. Management Consultant Former
Vantage Management Co., Inc. President Former
Plug Power Inc. Director Former
MTI Corporation Director Former
Mechanical Technology Inc. Director Former
Cree, Inc. Board of Directors Former
University of Illinois Ph.D. in chemical engineering Former
The Pennsylvania State University B.S. Former

Executive News

  • Boston Scientific Announces Retirement of Jim Tobin and Appointment of Ray Elliott as New President and CEO

    Yahoo! Canada - 6/25/09 - View Story

  • Boston Scientific Announces Retirement of Jim Tobin and Appointment of Ray Elliott as New President and CEO

    PR Newswire via Yahoo! - 6/25/09 - View Story

  • TARIS Biomedical Launches with $15 Million in Funding to Develop Innovative Drug-Device Therapies

    Pharma Live - 6/24/09 - View Story

  • Celgene Corporation to Present at Three Upcoming Investor Conferences

    Pharma Live - 6/09/09 - View Story

  • For MTI, a dose of much-needed relief: Struggling fuel-cell maker in line for stimulus funds from Energy Department

    TradingMarkets - 5/27/09 - View Story

advertisement
     CELG $46.73 -1.37 (-2.85% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 5,213,620
Shares Outstanding 460.29M
Market Cap 21.5B
Year High 77.39
Year Low 36.9
Earnings Per Share N/A
P/E Ratio -
Dividend N/A
Yield N/A
Glass Door

Pharma Industry Companies

Company Employer Rating
Pfizer 3.0
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement